crohn's disease and glp-1 Agonists Disease: Risks and Management SAFETY AND CLINICAL EFFECTIVENESS OF
Description
Buse, J.C
Isola S, Hussain A, Dua A
Current and potential therapeutic targets of glucagon-like peptide-2
Use of these drugs has surged: from 2019 to 2024 in the US, prescriptions for patients with obesity without diabetes rose by nearly 2,000%
The majority of GLP-1 medications are only approved for adults 18 years and older
